Facebook
Twitter
LinkedIn
ForwardBenjamin Maughan, M.D., PharmD
Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. He has been focused on studying resistance mechanisms to identify predictive biomarkers for systemic therapy as well as identifying novel treatments for all genitourinary cancers. For instance in metastatic prostate cancer he has been studying the role of resistance pathways including expression of truncated androgen receptors (ex. AR-V7 expression) and loss of tumor suppressors such as PTEN and Rb. Regarding novel treatment development he is the principle investigator for a number of investigator initiated clinical trials as well as the national lead investigator for SWOG 2200 testing a novel immune therapy combination in papillary renal cell carcinoma.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbvieDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AVEO OncologyDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstellasDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Bristol-Myers SquibbDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ClovisDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:TempusDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MerckDate added:05/06/2022Relationship end date:04/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ExelixisDate added:05/06/2022Relationship end date:04/01/2022